William Roberts

Search results

• FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression

  Roberts, W.

  23/08/23

  1 item of Media coverage

  Press/Media

• FDA APPROVES G1 THERAPEUTICS’ COSELA™ (TRILACICLIB): THE FIRST AND ONLY MYELOPROTECTION THERAPY TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION

  Roberts, W.

  18/02/21

  1 item of Media coverage

  Press/Media

• FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

  Roberts, W.

  15/02/21

  2 items of Media coverage

  Press/Media

• FDA Approves G1 Therapeutics’ COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

  Roberts, W.

  14/02/21

  1 item of Media coverage

  Press/Media

• FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

  Roberts, W.

  12/02/21 → 13/02/21

  29 items of Media coverage

  Press/Media